trial · primary record
Valganciclovir (Pre-emptive CMV Therapy)
Cytomegalovirus (CMV)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 360 |
| Primary completion | 2031-05-31 |
| Primary endpoint | Incidence of endpoint committee (EC)-confirmed CMV disease (either syndrome or end-organ) by 1-year post-transplant. |
| Registry ID | NCT06798909 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:02.549Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06798909
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.